IN2012DN01435A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01435A
IN2012DN01435A IN1435DEN2012A IN2012DN01435A IN 2012DN01435 A IN2012DN01435 A IN 2012DN01435A IN 1435DEN2012 A IN1435DEN2012 A IN 1435DEN2012A IN 2012DN01435 A IN2012DN01435 A IN 2012DN01435A
Authority
IN
India
Prior art keywords
coxibs
tramadol
nsaids
medicaments
pain
Prior art date
Application number
Other languages
English (en)
Inventor
Salaman Carlos Ramon Plata
Nicolas Tesson
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Priority claimed from PCT/EP2010/002385 external-priority patent/WO2011044962A1/fr
Publication of IN2012DN01435A publication Critical patent/IN2012DN01435A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN1435DEN2012 2008-10-17 2010-04-19 IN2012DN01435A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20080384012 EP2177215A1 (fr) 2008-10-17 2008-10-17 Co-cristaux de tramadol et NSAID
PCT/EP2009/007451 WO2010043412A1 (fr) 2008-10-17 2009-10-16 Co-cristaux de tramadol et d’ains
PCT/EP2010/002385 WO2011044962A1 (fr) 2009-10-16 2010-04-19 Co-cristaux de tramadol et de coxibs

Publications (1)

Publication Number Publication Date
IN2012DN01435A true IN2012DN01435A (fr) 2015-06-05

Family

ID=40673614

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1435DEN2012 IN2012DN01435A (fr) 2008-10-17 2010-04-19

Country Status (27)

Country Link
US (10) US20110257134A1 (fr)
EP (2) EP2177215A1 (fr)
JP (1) JP5645830B2 (fr)
KR (1) KR101679400B1 (fr)
CN (1) CN102186465B (fr)
AU (1) AU2009304235B2 (fr)
BR (1) BRPI0920358A2 (fr)
CA (1) CA2737754C (fr)
CY (1) CY1118374T1 (fr)
DK (1) DK2349238T3 (fr)
ES (1) ES2603962T3 (fr)
HR (1) HRP20161526T1 (fr)
HU (1) HUE030976T2 (fr)
IL (1) IL211785A (fr)
IN (1) IN2012DN01435A (fr)
LT (1) LT2349238T (fr)
MX (1) MX336318B (fr)
MY (1) MY156285A (fr)
NZ (1) NZ591873A (fr)
PL (1) PL2349238T3 (fr)
PT (1) PT2349238T (fr)
RU (1) RU2599717C2 (fr)
SI (1) SI2349238T1 (fr)
SM (1) SMT201600439B (fr)
UA (1) UA109534C2 (fr)
WO (1) WO2010043412A1 (fr)
ZA (1) ZA201102762B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
PL2488169T3 (pl) * 2009-10-16 2013-06-28 Esteve Pharmaceuticals Sa Kokryształy tramadolu i koksybów
EP2392319A1 (fr) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Composition pharmaceutique contenant des co-cristaux de tramadol et d'un coxib
WO2012009262A2 (fr) * 2010-07-12 2012-01-19 Yung Shin Pharm. Ind. Co., Ltd. Sel de diclofénac-tramadol
DE102010063609A1 (de) * 2010-12-20 2012-06-21 Awd.Pharma Gmbh & Co. Kg Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure
KR101888852B1 (ko) 2011-12-02 2018-09-21 삼성전자주식회사 휴대용 단말기에서 다이버시티 서비스를 제공하기 위한 장치 및 방법
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
ITMI20130210A1 (it) * 2013-02-14 2014-08-15 Menarini Lab Composizioni farmaceutiche contenenti dexketoprofene e tramadolo
RU2542100C1 (ru) * 2013-12-24 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN104592009B (zh) * 2015-02-09 2017-02-22 黑龙江大学 萘普生药物共晶及其制备方法
US9693949B1 (en) * 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
AU2018230350A1 (en) * 2017-03-08 2019-09-26 Intercept Pharmaceuticals, Inc Crystalline forms of obeticholic acid
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
WO2019130049A1 (fr) 2017-12-29 2019-07-04 Grünenthal GmbH Combinaison pharmaceutique comprenant du chlorhydrate de tramadol à libération prolongée et de l'étoricoxib à libération immédiate, et son utilisation pour le traitement de la douleur
US11510926B2 (en) 2018-05-31 2022-11-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pharmaceutical salts/co-crystals of pentoxifylline, clonidine and linsidomine with caffeic, protocatechuic or alpha-lipoic acid an use thereof for treatment of pain
WO2020039456A1 (fr) * 2018-08-20 2020-02-27 Mylan Laboratories Limited Co-cristal de tramadol hbr-célécoxib
WO2020121326A1 (fr) 2018-12-13 2020-06-18 Mylan Laboratories Limited (rac)-tramadol.hcl-célécoxib (1 : 1) amorphe
CA3137381A1 (fr) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Utilisation de co-cristaux de tramadol et de celecoxib pour traiter la douleur tout en reduisant le risque d'abus de tramadol
EP4169903A1 (fr) * 2021-10-25 2023-04-26 Dompe' Farmaceutici S.P.A. Co-cristaux de médicaments anti-inflammatoires non stéroïdiens, lysine et gabapentine, compositions pharmaceutiques et leur utilisation médicale
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
WO1993004675A1 (fr) 1991-09-06 1993-03-18 Mcneilab, Inc. Composition renfermant une matiere a base de tramadol et de l'acetaminophene, et son utilisation
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2276945C (fr) 1993-11-30 2006-08-01 G.D. Searle & Co. Pyrazolyle benzenesulfonamide tricyclique-substitue et leurs compositions pharmaceutiques
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
DE69739003D1 (de) 1996-04-12 2008-10-30 Searle Llc Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
PL187848B1 (pl) 1996-07-18 2004-10-29 Merck Frosst Canada Inc Podstawione pirydyny, kompozycja farmaceutyczna, podstawione pirydyny jako selektywne inhibitory cyklooksygenazy-2 oraz zastosowanie podstawionych pirydyn
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
CN1349423A (zh) * 1999-03-01 2002-05-15 奥索-麦克尼尔药品公司 包含曲马多物质和选择性cox－2抑制剂药物的组合物
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
EP1413294B1 (fr) 2001-07-27 2010-09-29 Astellas Pharma Inc. Composition contenant des grains fins a libération prolongée pour comprimés à désagrégation rapide dans la cavité buccale
WO2004078163A2 (fr) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN100418533C (zh) 2002-02-19 2008-09-17 阿德科克因格拉姆有限公司 环加氧酶-2抑制剂和阿片剂的药物组合体
EP1537258B9 (fr) 2002-07-17 2008-10-29 S.O.I.Tec Silicon on Insulator Technologies Procede de fabrication de substrats, en particulier pour l'optique, l'electronique ou l'optoelectronique
CN1245968C (zh) 2002-10-09 2006-03-22 新疆特丰药业股份有限公司 一种萘普生钠缓释片剂的制备方法
JP4469846B2 (ja) 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
EP1727520A2 (fr) 2003-12-09 2006-12-06 Medcrystalforms, Llc Procede de preparation de cocristaux a phase mixte avec des agents actifs
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
WO2008085674A1 (fr) 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant des co-cristaux de célécoxib
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
EP2022778A1 (fr) * 2007-08-07 2009-02-11 Laboratorios del Dr. Esteve S.A. Forme cristalline du sel de (R,R)-tramadol-(S)-naproxène
CN105254662A (zh) 2008-05-20 2016-01-20 阿索尔达治疗公司 水溶性对乙酰氨基酚类似物
EA023435B1 (ru) 2008-09-06 2016-06-30 Бионевия Фармасьютикалс, Инк. Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата
EP2177215A1 (fr) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
EP2311446A1 (fr) 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprenant du Tramadol et du Célécoxib pour le traitement de la douleur
PL2488169T3 (pl) * 2009-10-16 2013-06-28 Esteve Pharmaceuticals Sa Kokryształy tramadolu i koksybów
CN104817501B (zh) 2009-10-16 2017-09-22 埃斯蒂文博士实验室股份有限公司 曲马多与昔布类的共晶体
CA2797829A1 (fr) * 2010-05-07 2011-11-10 Carefusion 2200, Inc. Methode de production de pleurodese
EP2392319A1 (fr) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Composition pharmaceutique contenant des co-cristaux de tramadol et d'un coxib
CA3137381A1 (fr) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Utilisation de co-cristaux de tramadol et de celecoxib pour traiter la douleur tout en reduisant le risque d'abus de tramadol

Also Published As

Publication number Publication date
US8598152B2 (en) 2013-12-03
EP2349238B1 (fr) 2016-08-24
RU2599717C2 (ru) 2016-10-10
US11478488B2 (en) 2022-10-25
CN102186465A (zh) 2011-09-14
JP2012505847A (ja) 2012-03-08
RU2011119608A (ru) 2012-11-27
US10548909B2 (en) 2020-02-04
CA2737754C (fr) 2016-09-20
HUE030976T2 (en) 2017-06-28
US20150196504A1 (en) 2015-07-16
NZ591873A (en) 2012-12-21
SMT201600439B (it) 2017-01-10
IL211785A0 (en) 2011-06-30
JP5645830B2 (ja) 2014-12-24
ES2603962T3 (es) 2017-03-02
US20190231800A1 (en) 2019-08-01
LT2349238T (lt) 2016-12-27
MX336318B (es) 2016-01-14
AU2009304235B2 (en) 2015-05-07
AU2009304235A1 (en) 2010-04-22
US20170000806A1 (en) 2017-01-05
SI2349238T1 (sl) 2017-01-31
PT2349238T (pt) 2016-11-24
UA109534C2 (uk) 2015-09-10
CY1118374T1 (el) 2017-06-28
US9393220B2 (en) 2016-07-19
US20170027965A1 (en) 2017-02-02
WO2010043412A1 (fr) 2010-04-22
US10238668B2 (en) 2019-03-26
US10245276B2 (en) 2019-04-02
CN102186465B (zh) 2015-09-16
MY156285A (en) 2016-01-29
IL211785A (en) 2016-07-31
US9012440B2 (en) 2015-04-21
US20110257134A1 (en) 2011-10-20
EP2349238A1 (fr) 2011-08-03
PL2349238T3 (pl) 2017-06-30
US20120172398A1 (en) 2012-07-05
BRPI0920358A2 (pt) 2020-08-11
KR101679400B1 (ko) 2016-11-24
KR20110069860A (ko) 2011-06-23
EP2177215A1 (fr) 2010-04-21
US20140350110A1 (en) 2014-11-27
DK2349238T3 (en) 2016-12-12
MX2011003612A (es) 2011-05-10
CA2737754A1 (fr) 2010-04-22
US20140057879A1 (en) 2014-02-27
ZA201102762B (en) 2011-12-28
US20150196503A1 (en) 2015-07-16
HRP20161526T1 (hr) 2016-12-16
US20200171055A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
IN2012DN01435A (fr)
TN2012000515A1 (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
IN2012DN02805A (fr)
MY161088A (en) Agonists of gpr40
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
HK1140940A1 (en) Titration of tapentadol
HK1173380A1 (en) Co-crystals of tramadol and coxibs
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
GB0620385D0 (en) Novel compounds
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MY150931A (en) Substituted oxazolidinones and their use
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
TN2012000075A1 (en) Co-crystals of tramadol and coxibs
UA112981C2 (uk) Варіант людського gdnf
WO2010028130A3 (fr) Composés antidépresseurs
TN2011000617A1 (en) 17 - alkyl-17 -oxy-oestratrienes
WO2010027189A3 (fr) Nouvelle utilisation d'homo-isoflavanone ou d'un sel associe
TN2010000431A1 (en) New formulations, tablets comprising such formulations, their use and process for their preparation
UA42862U (uk) ЗАСТОСУВАННЯ М'ЯКОЇ ЛІКАРСЬКОЇ ФОРМИ, ЯКА МІСТИТЬ АКТИВНУ РЕЧОВИНУ β-ФЕНІЛЕТИЛАМІД 2-ОКСИСУКЦИНАНІЛОВОЇ КИСЛОТИ, ДЛЯ ЛІКУВАННЯ ОПІКОВИХ УРАЖЕНЬ ШКІРИ
EA200900174A8 (ru) Фармацевтическая композиция для лечения желудочных расстройств
EA201101708A1 (ru) Фармацевтическая композиция для лечения желудочных расстройств